BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com).

If you have any questions on BMJ Open’s open peer review process please email info.bmjopen@bmj.com
Medication adherence is protective of decompensation and mortality in HBV-related cirrhosis patients

| Journal:  | BMJ Open |
|-----------|----------|
| Manuscript ID:  | bmjopen-2021-059856 |
| Article Type:  | Original research |
| Date Submitted by the Author:  | 03-Dec-2021 |
| Complete List of Authors:  | Fu, Kuo-Yu; China Medical University, Department of Health Services Administration  
Hsieh, Meng-Lun; Taichung Veterans General Hospital Chiayi Branch, Department of Internal Medicine  
Chen, Jou-An; China Medical University, Department of Health Services Administration  
Hsieh, Vivian Chia-Rong; China Medical University, Department of Health Services Administration |
| Keywords:  | EPIDEMIOLOGY, Hepatology < INTERNAL MEDICINE, PUBLIC HEALTH |
I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd (“BMJ”) its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge (“APC”) for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author’s Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.
Original Paper

Medication adherence is protective of decompensation and mortality in HBV-related cirrhosis patients

Running title: Drug adherence in hepatitis B related cirrhosis

Kuo-Yu Fu, MHA#,1, Meng-Lun Hsieh, MD2, Jou-An Chen, MHA1, Vivian Chia-Rong Hsieh, PhD#,1,*

1 Department of Health Services Administration, China Medical University, Taichung 406, Taiwan;
2 Department of Internal Medicine, Taichung Veterans General Hospital Chiayi Branch, Chiayi 600, Taiwan;
# Contributed equally.

*Correspondence to:
Vivian Chia-Rong Hsieh, MSc, PhD.
Department of Health Services Administration,
China Medical University
No. 100, Sec. 1, Jingmao Rd.,
Beitun District, Taichung 406, Taiwan
Email: hsiehchiarong@gmail.com

Word count: 2,608
Tables: 4
Figures: 0
Abstract

Objectives
To evaluate the medication adherence among CHB-related cirrhosis patients with decompensation and mortality, and to analyze the effect of medication adherence on the patients’ prognosis.

Participants
Two prognosis end points (decompensation and mortality) were used respectively to classify study subjects into two different case-control sets in this retrospective case-control study.

Outcome measures
Decompensation and mortality were defined from 2007 to 2016 using a population-based medical claims database. Medication possession ratio (MPR) was used as a measure of treatment adherence.

Results and conclusion
Between decompensated and compensated patients, longer term treatment adherence is seen higher in the compensated group versus the decompensated group: 1-year MPR (0.65±0.43 vs. 0.57±0.53), and 6-month MPR (0.79±0.52 vs. 0.76±0.79). On the contrary, 3-month adherence is higher in the decompensated group (1.00±1.15 vs. 0.96±0.79). For patients with and without mortality, drug adherence is ubiquitously higher in the alive group regardless of follow-up length: 1-year MPR (0.62±0.44 vs. 0.50±0.51), 6-month MPR (0.78±0.62 vs. 0.69±0.72) and 3-month MPR (0.97±0.91 vs. 0.96±1.12). After accounting for confounding variables, we find that the likelihood of complicated cirrhosis is significantly lower in more adherent patient and the benefit increases with more persistent adherence (log 1-year MPR OR: 0.75, 95% CI: 0.73-0.77). Similar results are observed for the adjusted likelihood of mortality.

Adherence to antiviral therapy lowers risk for decompensation compared with those
with nonadherence, and also reduces overall risk for death in cirrhotic patients.

Keywords: cirrhosis; hepatitis B; medication adherence; prognosis

Strengths and Limitations of this study:

- No study has yet provided empirical evidence on the adherence rate of cirrhosis patients on antiviral therapy and quantified the level of adherence required to avert adverse outcomes.

- Medication possession ratio (MPR) can be a robust estimate of treatment adherence over time as it takes into account the period when patient stops and resumes medication.

- This is a population-based case-control study using nationwide claims data, and the distribution of general characteristics of our study subjects appears to be similar to the general demographics of HBV-related cirrhosis patients.

- We had no imaging data or laboratory test results to confirm the severity or the diagnosis of cirrhosis in each of our subjects.

- Adherent level estimated using MPR may not represent the actual medication adherence exhibited by the study subjects as it was calculated based on prescription history and not the actual uptake of medication by the patients.
Introduction

With the growing prevalence of chronic diseases globally, medication adherence to therapy has become one of the highly concerned issues in recent years. Patient adherence refers to the extent to which a patient complies with the doctor's orders or recommendations given by a healthcare provider. Unfortunately, patient adherence is generally not high. Statistics indicate that only about 50% of chronic disease patients worldwide taking medications in accordance with doctors' orders. This result not only leads to poor clinical treatment results, but also increases mortality and generates substantial economic burden (Celio et al, 2018).

Cirrhosis is an irreversible liver disease characterized by poor liver function due to long-term damage like alcohol use or viral infections such as chronic hepatitis B (CHB) and chronic hepatitis C (CHC). In southeast Asian nations, CHB- and CHC-related cirrhosis is particularly prevalent (GBD 2017 Cirrhosis Collaborators, 2020). According to its natural clinical course and symptoms, cirrhosis can be divided into two stages of compensated (CC) and decompensated cirrhosis (DC). The former stage is characterized by an absence of complications, whereas the latter is an advanced condition with life-threatening conditions develop from elevated portal hypertension. DC is associated with complications such as varicose bleeding, ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, and hepatic encephalopathy (EASL, 2018). Previous findings suggest that the median survival time for patients with CC is 12 years and the treatment rate is about 70-80%, while the median survival time for patients with DC is less than two years and the treatment rate is about 50-60% (D’Amico et al, 2006; Shah and Amarapurkar, 2018). Other related literature also showed that the death rate of patients with DC is 4 times that of healthy individuals, 30% of patients die within one month, and 63% of patients die within one year (Arvaniti et al., 2010).
For the treatment of cirrhosis, antiviral therapy has shown positive effect on the improvement of cirrhosis and its complications (Peng et al, 2012; Piotrowski and Boron-Kaczmarska, 2017). However, treatment adherence in chronic patients is usually not high, as they may have low perception of the effectiveness or necessity of prescribed medications (Horne et al, 2013; Hayward et al, 2017). There is a scarcity of studies illustrating the benefits of maintaining adherence with viral hepatitis-related cirrhosis patients. Moreover, as many studies have discussed the advantages of good treatment adherence, no study has yet provided empirical evidence on the pragmatic adherence rate of cirrhosis patients on antiviral therapy and quantified the level of adherence required to avert adverse outcomes, e.g., how adherent are cirrhotic patients to their treatment regimens and how adherent is sufficient to prevent disease progression reduce complication risks among these patients.

The objective of present study was to first compare the medication adherence between CHB-related cirrhosis patients with and without decompensation, and to subsequently analyze the effect of medication adherence on the patients’ prognosis (decompensation and mortality). To ensure that both short- and long-term adherence is considered, medication possession ratio was calculated for three-month, six-month and one-year periods.

Materials and Methods

Study design and subject selection

This is a retrospective case-control study using secondary data from administrative claims-based database released by the Health and Welfare Data Science Center, Ministry of Health and Welfare (HWDC, MOHW), Taiwan. Patients who were aged over 20 years old and diagnosed with chronic hepatitis B (ICD-9-CM: 5
070.32, 070.33, V02.61) and cirrhosis (571.4, 571.5, 571.8) were first identified from the database. To ensure that the cirrhosis of our study sample is derived from hepatitis B, patients diagnosed with the following conditions were excluded: alcoholic fatty liver cirrhosis (571.0), alcoholic cirrhosis (571.11, 571.2, 571.3), biliary cirrhosis (571.6), congenital cirrhosis (777.8), hemochromatosis (275.0), or the syphilitic cirrhosis (095.3). Observation period starts from 2007 and ends in 2016 for a total of 10 years.

Two prognosis end points were used respectively to classify study subjects into two different case-control sets: 1) presence of complications (case: decompensated cirrhosis, control: compensated cirrhosis), 2) mortality (case: dead, control: alive). Decompensation was defined when the subject had been diagnosed with at least one of the following conditions: esophageal variceal bleeding (456.0), ascites (789.5), spontaneous bacterial peritonitis (567.23), hepatorenal syndrome (572.4), and hepatic encephalopathy (572.2), while compensation was considered in the absence of any of the above complications. Mortality was ascertained if death was recorded after the date of diagnosis for cirrhosis. Each case-control set was matched 1:1 using propensity score matching according to gender, age, and post-onset medication interval. Post-onset medication interval was to ensure that the case and control patients were not too far apart in terms of their medical history (i.e., how long since they have been diagnosed with hepatitis B).

Medication and adherence measurements

Five antiviral drugs have been approved for the treatment of HBV infection in patients with relevant indications. In this study, HBV patients treated with nucleos(t)ide analogues (NUCs) were identified: lamivudine (LAM), adefovir dipivoxil (ADV), telbivudine (LdT), entecavir (ETV) and tenofovir disoproxil
fumarate (TDF). Medication possession ratio (MPR) was calculated for 3, 6, and 12 months prior to the date of prognosis in patients that were being prescribed with the antiviral medication(s). For controls, MPR was estimated for 3, 6, and 12 months prior to the end of the observation period. MPR is a commonly-used indirect measure of drug adherence and refers to the proportion of days a patient has a supply of drugs during the observation period. When there are multiple medications, the amount of prescription drugs is taken into account in the denominator. Good adherence is when the MPR is greater than 0.75 or 0.80. However, if the MPR is higher than 1, there is the possibility of overdose and overlap-use of the patient. Most studies use 0.80 as a cut-off point for determining good or poor adherence.

Statistical analyses

SAS version 9.4 statistical software package was used to perform statistical analyses in this study. Patient characteristics and treatment methods were descriptively analyzed, and the results were presented in the form of means, standard deviations, frequencies, percentage, etc. For the distribution statistics and continuous data comparison between the groups, Wilcoxon’s rank-sum test was used. For categorical variables such as patient traits and treatment modalities, Chi-square test or Fisher's exact test was used to test the differences between study groups. Collinearity test was conducted to exclude any variables with collinearity problems. Natural logarithm (log) of MPR was also taken to standardize its distribution. Finally, for inferential statistics, conditional logistic regression models were used to estimate the odds of prognosis (decompensation or mortality) after accounting for MPR and other covariates. Odds ratio (OR) and 95% confidence interval for poor prognosis are presented as results in the included tables.
Ethics approval

This study was approved by China Medical University and Hospital ethics committee (CMUH107-REC2-105) and was supported by the following grants: MOST 107-2314-B-039 -065 -MY3 and CMU107-Z-04.

Results

From the population-based database, a total of 10,180 decompensated cirrhosis and 10,180 compensated cirrhosis patients are matched. Similarly, 9,724 patients who died from cirrhosis and 9,724 cirrhosis patients who are alive during the study period are identified and matched. In general, regardless of the prognosis (decompensation or death), medication adherence increases as time approaches closer to the time of adverse outcome (Table 1). For example, 1-year, 6-month, and 3-month MPRs in decompensated and compensated cirrhotic subjects are 0.61±0.48, 0.77±0.67, and 0.98±0.99, respectively. A slightly lower MPR but similar pattern is found when we examined MPR in cirrhosis patients with and without mortality: 1-year, 6-month, and 3-month MPRs are 0.56±0.48, 0.74±0.67, and 0.97±1.02. It is worthy to note that long term (>3-month) MPRs are all shown to be under 0.80.

Table 2 shows the post-matching characteristics of study subject groups divided by prognosis. In decompensated group, 34.8% (n=3,542) of patients experienced 2 or more complications, 33.6% (n=3,424) had ascites, while the compensated control group had no complications as expected. The pattern of NUC uptake differs significantly between the two groups: the top three most commonly used NUCs in decompensated patients are ETV (61.1%), LAM (14.2%), and TDF (10.4%), and ETV (59.6%), TDF (19.8%), LAM (9.58%) in compensated patients. The proportion of patients undergoing more than two NUC treatments is relatively higher in
complicated cirrhosis patients (7.11% vs. 4.93%; p<0.001). Longer term treatment adherence seems higher on average in the compensated group versus decompensated group: 1-year MPR (0.65±0.43 vs. 0.57±0.53), and 6-month MPR (0.79±0.52 vs. 0.76±0.79). On the contrary, 3-month adherence is higher in the decompensated group (1.00±1.15 vs. 0.96±0.79).

In the set of analysis examining mortality as outcome, the occurrence of every complication is significantly higher in cirrhosis patients who died (cases) than in those who are still alive (controls) (Table 2). Most pronounced difference is seen in two or more concurrent complications (23.5% vs. 2.93%) and ascites (15.4% vs. 4.65%). Most of the control patients do not experience any complication (88.6%) unlike the case patients with just 45.5%. Drug adherence is ubiquitously higher in the alive group regardless of length of follow-up (p<0.001): 1-year MPR (0.62±0.44 vs. 0.50±0.51), 6-month MPR (0.78±0.62 vs. 0.69±0.72) and 3-month MPR (0.97±0.91 vs. 0.96±1.12).

After accounting for confounding variables, we find that the likelihood of complicated cirrhosis is significantly lower in more adherent patients. In the results from multivariate analysis presented in Table 3, longer persistent adherence (log 1-year MPR) is associated with most apparent decreased odds of decompensation (OR: 0.75, 95% CI: 0.73-0.77, p<0.001). Likelihood for the poor prognosis slightly elevates when adherence continues for shorter span: log 6-month MPR (OR: 0.79, 95% CI: 0.76-0.81, p<0.001), and log 3-month MPR (OR: 0.85, 95% CI: 0.83-0.88, p<0.001). Older age is also found to be related to slightly increased odds of decompensation (p<0.001).

Similar results are observed for the adjusted likelihood of mortality: better adherence is also associated with lower chance of mortality particularly with longer adherence: log 1-year MPR (OR: 0.70, 95% CI: 0.68-0.72, p<0.001), log 6-month...
MPR (OR: 0.72, 95% CI: 0.69-0.75, p<0.001), and log 3-month MPR (OR: 0.78, 95% CI: 0.75-0.81, p<0.001) (Table 4). In addition, having two or more complications considerably increases the odds of mortality by 16-fold which is much higher than the other complication categories. Contrary to the increased risk of mortality imposed by older age, the use of NUCs generally averts patients from the adverse event.

Discussion

The present study provides information from a nationwide retrospective study of cirrhosis patients 20 years and older induced by viral hepatitis B. Unfortunately, despite Taiwan’s readily accessible universal coverage health care system, patient adherence to therapy of cirrhosis remains inadequate, particularly in the long run (i.e., 1-year MPR: 0.56-0.61). This finding is consistent with previous studies examining adherent behavior in CHB patients from other countries (Allard et al, 2017; Xu et al, 2018). More importantly, we demonstrated that adherent behavior generally reduces the likelihood of poor prognosis, and the benefits of long-term adherence is evidently more pronounced than that of the short-term. The fact that patient adherence greatly escalates during the short time leading up to adverse outcomes indicates that patients’ healthcare seeking behaviors are still very reactive rather than proactive (i.e., proactive behavior should indicate a consistent pattern of medication use since the point of diagnosis, and not particularly prior to the occurrence of complications). Furthermore, the occurrence of complications, such as HRS and HE, exacerbates the likelihood of mortality, especially if two or more are collectively observed.

Treatment adherence has been widely proven to be associated with better virology response and patient-reported outcomes in patients with CHB infection prior to the development of cirrhosis (Allard et al, 2020; Grossi et al, 2017; Lieveld et al,
2013; Younossi et al, 2019). Results of this study, however, showed that adherence to antiviral therapy effectively prevents the development of subsequent complications and death among HBV-related cirrhosis patients. After accounting for other confounding characteristics such as gender, age, type of complications, and treatment methods, this association still remained statistically significant. Therefore, we confirm that the better the patient's medication adherence, the lower their risk of subsequent poor prognosis. This is similar to a Taiwanese cohort study of 1315 treatment-naïve CHB-related cirrhosis patients; it is found that 4-year ETV therapy significantly decreases patients’ risk of cirrhotic complications and all-cause mortality (Su et al, 2016). Another study conducted in Korean CHB patients revealed that poor adherence to ETV therapy was associated with increased risk of cirrhotic complications and all-cause mortality (Shin et al, 2018). As Taiwan offers universal coverage to healthcare and financial support to low-income households, affordability of medication should not be a chief barrier to nonadherence as past studies have suggested (Hayward et al, 2017; Xu et al, 2018). It is possible that, under our context of study, poor adherence may be due to patients’ low perception of treatment benefit or their reluctance to comply without experiencing obvious symptoms (Hayward et al, 2017). Nevertheless, there have also been studies that reported very good medication adherence to NUCs among patients with CHB. A US study using self-reported survey found an adherence rate of 100% in 74.1% of its subjects (Chotiyaputta et al, 2012). Another study from the Netherlands reported 70% of CHB patients presented an adherence rate of over 80% towards entecavir (van Vlerken et al, 2015). It is possible that the factors and the barriers associated with adherence to antiviral treatment among CHB patients are context- and/or culture-specific (Kidd and Altman, 2000).

The distribution of general characteristics of our study subjects appears to be similar to the general demographics of HBV-related cirrhosis patients; here we find
that these patients are mostly male with a mean age of approximately 60 years, which is similar to the demographics found in past studies (Hung et al., 2019; Rubin et al., 2020). Among the used NUCs, patients have been predominantly prescribed entecavir as it is still considered a first-line treatment for patients with CHB (Chien et al., 2019). The use of MPR as a measure of drug adherence has also been adopted in many previous studies (Friedman et al, 2007; Allard et al, 2020; Zhang et al, 2014). It is believed that MPR can be a robust estimate of treatment adherence over time as it takes into account the period when patient stops and resumes medication (Friedman et al, 2007).

Nevertheless, our study is not without limitations. First, the primary source of data for this study was a medical claims-based database, hence, MPR was calculated based on prescription history and not the actual uptake of medication by the patients. Hence, the adherent level estimated using MPR may not represent the actual medication adherence exhibited by the study subjects. Second, although population-based claims database provided us with an opportunity to study patient adherence in a large scale, we had no imaging data or laboratory test results to confirm the severity or the diagnosis of cirrhosis in each of our subjects. Therefore, the variability in patients’ conditions and their consequent probability of disease progression could not be considered. Other important factors leading up to adverse prognosis may not be explored, including time since diagnosis and lifestyle factors. Nonetheless, with the high prevalence of HBV in the context under study, we had obtained a sufficient sample size for analyses and estimates for robust results.

In conclusion, findings of this study demonstrate that prompt follow-up and strict adherence to prescribed antiviral therapy should be highly endorsed in patients with HBV-related cirrhosis particularly by doctors, while a lack of adherence or non-adherence would lead to pervasive threat to patients’ health, including transition to
decompensation state and possible death. We hope that findings of this study would shed some light for future studies which may aim to investigate the rolling out of policies targeting the context-specific factors associated with poor adherence in cirrhosis patients, possibly including enhanced adherence counselling in clinical setting.
Summary of Study

The objective of present study was to first compare the medication adherence between CHB-related cirrhosis patients with and without decompensation, and subsequently to analyze the effect of medication adherence on the patients’ prognosis (decompensation and mortality). Using medication-possession ratio as a measure for adherence, we find that patient adherence to therapy of cirrhosis remains inadequate compared with other countries. The lack of adherent behavior, particularly in the long run, may significantly diminish the potential benefits of treatment intervention.

Acknowledgments

We would like to thank Dr. Cheng-Yuan Peng for his valuable input and contribution to this study. This project is supported in part by Taiwan’s Ministry of Science and Technology (MOST 107-2314-B-039-065-MY3) and China Medical University (CMU107-Z-04).

Conflicts of interests

The authors disclose no potential financial or nonfinancial conflict of interests.

Author Statement

VCR Hsieh is guarantor of the article.

KY Fu, JA Chen, and VCR Hsieh were involved in design, data collection, interpretation and preparation of the initial manuscript.

ML Hsieh and VCR Hsieh were involved in critically appraising and revising the manuscript prior to approving the final version.

All authors approved the final version of the manuscript and the authorship list.
References

Allard N, Dev A, Dwyer J, Srivatsa G, Thompson A, Cowie B. Factors associated with poor adherence to antiviral treatment for hepatitis B. J Viral Hepat 2017;24:53-58.

Allard NL, MacLachlan JH, Dev A, et al. Adherence in chronic hepatitis B: associations between medication possession ratio and adverse viral outcomes. BMC Gastroenterol 2020;20:140.

Arvaniti V, D'Amico G, Fede G, Manousou P, Tsochatzis E, Pleguezuelo M, Burroughs AK. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 2010;139:1246-1256, 1256.e1-5.

Celio J, Ninane F, Bugnon O, Schneider MP. Pharmacist-nurse collaborations in medication adherence-enhancing interventions: A review. Patient Educ Couns 2018;101:1175-1192.

Chien R, Kao JH, Peng CY, et al. Taiwan consensus statement on the management of chronic hepatitis B. J Formos Med Assoc 2019;118:7-38.

Chotiyaputta W, Hongthanakorn C, Oberhelman K, Fontana RJ, Licari T, Lok ASF. Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical practice and correlation with virological breakthroughs. J Viral Hepat 2012;19:205-212.

D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44:217-231.

European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018;69:406-460.

Friedman DS, Quigley HA, Gelb L, et al. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS). Invest Ophthalmol Vis Sci 2007;48:5052-5057.

GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol 2020;5:245-266.

Grossi G, Viganò M, Loglio A, Lampertico P. Hepatitis B virus long-term impact of
antiviral therapy nucleotide analogues (NUCs). Liver Int 2017;37 Suppl 1:45-51.

Hayward KL, Valery PC, Martin JH, et al. Medication beliefs predict medication adherence in ambulatory patients with decompensated cirrhosis. World J Gastroenterol 2017;23:7321-7331.

Horne R, Chapman SCE, Parham R, Freemantle N, Forbes A, Cooper V. Understanding patients' adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the Necessity-Concerns Framework. PLoS One 2013;8:e80633.

Hung TH, Tsai CC, Lee HF. Population-based study of Entecavir and long-term mortality in chronic hepatitis B–related decompensated liver cirrhosis. Clin Res Hepatol Gastroenterol 2019;43:694-699.

Kidd KE, Altman DG. Adherence in social context. Control Clin Trials. 2000;21:184S-187S.

Lieveld FI, van Vlerken LG, Siersema PD, van Erpecum KJ. Patient adherence to antiviral treatment for chronic hepatitis B and C: a systematic review. Ann Hepatol 2013;12:380-391.

Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol 2012;57:442-450.

Piotrowski D, Boroń-Kaczmarska A. Bacterial infections and hepatic encephalopathy in liver cirrhosis-prophylaxis and treatment. Adv Med Sci 2017;62:345-356.

Rubin JB, Sundaram V, Lai JC. Gender differences among patients hospitalized with cirrhosis in the United States. J Clin Gastroenterol 2020;54:83-89.

Shah AS, Amarapurkar DN. Natural history of cirrhosis of liver after first decompensation: a prospective study in India. J Clin Exp Hepatol 2018;8:50-57.

Shin JW, Jung SW, Lee SB, et al. Medication nonadherence increases hepatocellular carcinoma, cirrhotic complications, and mortality in chronic hepatitis B patients treated with entecavir. Am J Gastroenterol 2018;113:998-1008.

Su TH, Hu TH, Chen CY et al. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int 2016;36:1755-1764.

van Vlerken L, Arends P, Lieveld FI, et al. Real life adherence of chronic hepatitis B patients to entecavir treatment. Dig Liver Dis 2015;47:577-583.
Xu K, Liu LM, Farazi PA, et al. Adherence and perceived barriers to oral antiviral therapy for chronic hepatitis B. Glob Health Action 2018;11:1433987.

Younossi ZM, Stepanova M, Younossi I, et al. Long-term effects of treatment for chronic HBV infection on patient-reported outcomes. Clin Gastroenterol Hepatol. 2019;17:1641-1642.e1.

Zhang Y, Kaplan CM, Baik SH, Chang CH, Lave JR. Medication adherence and readmission after myocardial infarction in the Medicare population. Am J Manag Care 2014;20:e498-505.
Table 1. Descriptive statistics of medication adherence and prognosis among chronic hepatitis B virus-related cirrhosis patients.

| Dependent variable | Medication Adherence (MPR) | Mean | Standard deviation | Median |
|--------------------|-----------------------------|------|--------------------|-------|
| Decompression      | 3-month                     | 0.98 | 0.99               | 0.93  |
|                    | 6-month                     | 0.77 | 0.67               | 0.74  |
|                    | 1-year                      | 0.61 | 0.48               | 0.54  |
| Death              | 3-month                     | 0.97 | 1.02               | 0.92  |
|                    | 6-month                     | 0.74 | 0.67               | 0.67  |
|                    | 1-year                      | 0.56 | 0.48               | 0.46  |
Table 2. Post-matching characteristic profile of cirrhosis subjects by prognosis (decompensation/compensation; and death/alive).

| Variable                  | Decompensated | Compensated | P-value | Death    | Alive    | P-value |
|---------------------------|---------------|-------------|---------|----------|----------|---------|
|                           | n             | %           | n       | %       | n        | %       |         |
| Total                     | 10,180        | 50.0        | 10,180  | 50.0    | 9,724    | 50.0    | 1.00     |
| Sex                       |               |             |         |         |          |         | 1.00     |
| Male                      | 7,453         | 73.2        | 7,453   | 73.2    | 7,780    | 80.0    | 7,780    | 80.0    |
| Female                    | 2,727         | 26.8        | 2,727   | 26.8    | 1,944    | 20.0    | 1,944    | 20.0    |
| Age (mean, SD)            | 60.1          | 12.0        | 59.7    | 12.0    | 60.4     | 12.0    | 60.0     | 12.0    |
| Complications             |               |             |         |         |          |         | 0.06     |
| Varicose vein bleeding    | 526           | 5.2         | 0       | 0       | 156      | 1.60    | 46       | 0.47    |
| Ascites                   | 3,424         | 33.6        | 0       | 0       | 1,498    | 15.4    | 452      | 4.65    |
| SBP                       | 414           | 4.07        | 0       | 0       | 187      | 1.92    | 57       | 0.59    |
| HRS                       | 153           | 1.50        | 0       | 0       | 101      | 1.04    | 18       | 0.19    |
| HE                        | 2,121         | 20.8        | 0       | 0       | 1,078    | 11.1    | 247      | 2.54    |
| Two or more               | 3,542         | 34.8        | 0       | 0       | 2,281    | 23.5    | 285      | 2.93    |
| None                      | 0             | 0           | 10,180  | 100.0   | 4,423    | 45.5    | 8,619    | 88.6    |
| NUCs                      |               |             |         |         |          |         | <0.001   |
| LAM                       | 1,448         | 14.2        | 975     | 9.58    | 1,352    | 13.9    | 1,117    | 11.5    |
| ADV                       | 74            | 0.73        | 85      | 0.83    | 77       | 0.79    | 83       | 0.85    |
| LdT                       | 656           | 6.44        | 533     | 5.24    | 759      | 7.81    | 533      | 5.48    |
| ETV                       | 6,216         | 61.1        | 6,065   | 59.6    | 5,912    | 60.8    | 5,693    | 58.6    |
| TDF                       | 1,062         | 10.4        | 2,020   | 19.8    | 917      | 9.43    | 1,881    | 19.3    |
| Two or more combined      | 724           | 7.11        | 502     | 4.93    | 707      | 7.27    | 417      | 4.29    |
| MPR (mean, SD)            |               |             |         |         |          |         | <0.001   |
| 3-month                   | 1.00          | 1.15        | 0.96    | 0.79    | 0.96     | 1.12    | 0.97     | 0.91    |
| 6-month                   | 0.76          | 0.79        | 0.79    | 0.52    | 0.69     | 0.72    | 0.78     | 0.62    |
| 1-year                    | 0.57          | 0.53        | 0.65    | 0.43    | 0.50     | 0.51    | 0.62     | 0.44    |

Abbreviations: SBP, spontaneous bacterial peritonitis; HRS, hepatorenal syndrome; HE, hepatic encephalopathy. NUCs, nucleos(t)ide analogues; LAM, lamivudine only; ADV, adefovir dipivoxil only; LdT, telbivudine only; ETV, entecavir only; TDF, tenofovir disoproxil fumarate only; MPR, medication possession ratio.
Table 3. Conditional logistic regression analysis of decompensation in cirrhosis patients.

| Variable            | Crude | After adjusting -log Three-months MPR | After adjusting -log Six-months MPR | After adjusting -log One-year MPR |
|---------------------|-------|----------------------------------------|-----------------------------------|----------------------------------|
|                     | OR    | 95% CI                                 | P-value                          | OR                              | 95% CI                      | P-value                   | OR                              | 95% CI                      | P-value                   |
| Medication adherence|       |                                        |                                   |                                 |                               |                           |                                 |                               |                           |
| log 3-month MPR     | 0.85  | 0.82 0.88                              | <0.001                           | 0.85                            | 0.83 0.88                    | <0.001                    | 0.79                            | 0.76 0.81                    | <0.001                    |
| log 6-month MPR     | 0.78  | 0.76 0.81                              | <0.001                           | 0.79                            | 0.76 0.81                    | <0.001                    | 0.79                            | 0.76 0.81                    | <0.001                    |
| log 1-yr MPR        | 0.75  | 0.73 0.77                              | <0.001                           | 0.75                            | 0.73 0.77                    | <0.001                    | 0.75                            | 0.73 0.77                    | <0.001                    |
| Age                 | 1.04  | 1.03 1.04                              | <0.001                           | 1.04                            | 1.03 1.04                    | <0.001                    | 1.03                            | 1.03 1.04                    | <0.001                    |
| NUCs                |       |                                        |                                   |                                 |                               |                           |                                 |                               |                           |
| LAM                 | 1.08  | 0.94 1.25                              | 0.27                             | 1.09                            | 0.95 1.27                    | 0.22                      | 1.12                            | 0.97 1.29                    | 0.14                      | 1.16 1.00 1.35 | 0.04 |
| ADV                 | 0.63  | 0.45 0.88                              | 0.007                            | 0.63                            | 0.45 0.88                    | 0.007                     | 0.64                            | 0.45 0.90                    | 0.01                      | 0.68 0.48 0.96 | 0.03 |
| LdT                 | 0.88  | 0.75 1.04                              | 0.14                             | 0.89                            | 0.76 1.05                    | 0.18                      | 0.92                            | 0.78 1.08                    | 0.30                      | 0.95 0.81 1.13 | 0.58 |
| ETV                 | 0.73  | 0.65 0.83                              | <0.001                           | 0.73                            | 0.65 0.83                    | <0.001                    | 0.75                            | 0.67 0.85                    | <0.001                    | 0.79 0.70 0.89 | <0.001 |
| TDF                 | 0.38  | 0.33 0.43                              | <0.001                           | 0.38                            | 0.33 0.44                    | <0.001                    | 0.39                            | 0.34 0.45                    | <0.001                    | 0.41 0.36 0.48 | <0.001 |
| Two or more combined treatments | 1 | 1 |                                 | 1 | 1 |                           | 1 | 1 |                           | 1 | 1 |

NUCs, nucleos(t)ide analogues; LAM, lamivudine only; ADV, adefovir dipivoxil only; LdT, telbivudine only; ETV, entecavir only; TDF, tenofovir disoproxil fumarate only; MPR, medication possession ratio.
Table 4. Conditional Logistic regression analysis of mortality in cirrhosis patients.

| Variable                      | Crude | After adjusting -log Three-months MPR | After adjusting -log Six-months MPR | After adjusting -log One-year MPR |
|-------------------------------|-------|----------------------------------------|-------------------------------------|-----------------------------------|
|                               | OR    | 95% CI       | P-value | OR   | 95% CI       | P-value | OR   | 95% CI       | P-value |
| Medication adherence          |       |              |         |      |              |         |      |              |         |
| log 3-month MPR               | 0.80  | 0.78        | 0.83    | <0.001 | 0.78        | 0.75    | 0.81  | <0.001 |
| log 6-month MPR               | 0.72  | 0.70        | 0.74    | <0.001 | 0.72        | 0.69    | 0.75  | <0.001 |
| log 1-yr MPR                  | 0.69  | 0.67        | 0.71    | <0.001 | 0.70        | 0.68    | 0.72  | <0.001 |
| Age                           | 1.04  | 1.03        | 1.05    | <0.001 | 1.03        | 1.02    | 1.04  | <0.001 |
| Complications                 |       |              |         |      |              |         |      |              |         |
| Varicose vein bleeding        | 6.0   | 4.20        | 8.83    | <0.001 | 6.57        | 4.53    | 9.52  | <0.001 |
| Ascites                       | 6.73  | 5.90        | 7.67    | <0.001 | 6.58        | 5.76    | 7.50  | <0.001 |
| SBP                           | 7.41  | 5.28        | 10.4    | <0.001 | 7.22        | 5.12    | 10.2  | <0.001 |
| HRS                           | 12.5  | 7.17        | 21.9    | <0.001 | 12.7        | 7.18    | 22.5  | <0.001 |
| HE                            | 9.18  | 7.76        | 10.9    | <0.001 | 8.98        | 7.58    | 10.6  | <0.001 |
| Two or more combined treatments | 15.7  | 13.5        | 18.2    | <0.001 | 16.1        | 13.8    | 18.7  | <0.001 |
| None                          | 1     | 1           | 1       |       | 1           | 1       | 1     |       |
| NUCs                          |       |              |         |      |              |         |      |              |         |
| LAM                           | 0.71  | 0.61        | 0.82    | <0.001 | 0.71        | 0.59    | 0.85  | <0.001 |
| ADV                           | 0.55  | 0.39        | 0.77    | <0.001 | 0.65        | 0.43    | 0.97  | 0.04  |
| LdT                           | 0.84  | 0.71        | 1.00    | 0.04  | 1.00        | 0.82    | 1.23  | 0.99  |
| ETV                           | 0.62  | 0.54        | 0.70    | <0.001 | 0.72        | 0.62    | 0.84  | <0.001 |
| TDF                           | 0.29  | 0.25        | 0.34    | <0.001 | 0.41        | 0.34    | 0.49  | <0.001 |
| Two or more combined treatments | 1     | 1           | 1       |       | 1           | 1       | 1     |       |
SBP, spontaneous bacterial peritonitis; HRS, hepatorenal syndrome; HE, hepatic encephalopathy. NUCs, nucleos(t)ide analogues; LAM, lamivudine only; ADV, adefovir dipivoxil only; LdT, telbivudine only; ETV, entecavir only; TDF, tenofovir disoproxil fumarate only; MPR, medication possession ratio.
Reporting checklist for case-control study.

Based on the STROBE case-control guidelines.

**Instructions to authors**

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the STROBE case-control reporting guidelines, and cite them as:

von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

| Reporting Item | Page Number |
|----------------|-------------|
| Title and abstract | | |
| Title | #1a | Indicate the study’s design with a commonly used term in the title or the abstract | p.1 |
| Abstract | #1b | Provide in the abstract an informative and balanced summary | p.2 |
of what was done and what was found

**Introduction**

Background / rationale

#2 Explain the scientific background and rationale for the investigation being reported

Objectives

#3 State specific objectives, including any prespecified hypotheses

**Methods**

Study design

#4 Present key elements of study design early in the paper

Setting

#5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection

Eligibility criteria

#6a Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls. For matched studies, give matching criteria and the number of controls per case

Eligibility criteria

#6b For matched studies, give matching criteria and the number of controls per case

#7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable

Data sources / measurement

#8 For each variable of interest give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one
group. Give information separately for cases and controls.

Bias  #9  Describe any efforts to address potential sources of bias  NA

Study size  #10  Explain how the study size was arrived at  p.5-6

Quantitative #11  Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why  p.12

Statistical methods  #12a  Describe all statistical methods, including those used to control for confounding  p.7

Statistical methods  #12b  Describe any methods used to examine subgroups and interactions  NA

Statistical methods  #12c  Explain how missing data were addressed  NA

Statistical methods  #12d  If applicable, explain how matching of cases and controls was addressed  p.6

Statistical methods  #12e  Describe any sensitivity analyses  NA

Results

Participants  #13a  Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed. Give information separately for cases and controls.  p.8

Participants  #13b  Give reasons for non-participation at each stage  NA
Participants  
#13c Consider use of a flow diagram  NA

Descriptive data  
#14a Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders. Give information separately for cases and controls  p.8

Descriptive data  
#14b Indicate number of participants with missing data for each variable of interest  NA

Outcome data  
#15 Report numbers in each exposure category, or summary measures of exposure. Give information separately for cases and controls  p.8

Main results  
#16a Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included  p.8-9

Main results  
#16b Report category boundaries when continuous variables were categorized  p.8-9

Main results  
#16c If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period  NA

Other analyses  
#17 Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses  NA

Discussion

Key results  
#18 Summarise key results with reference to study objectives  p.10-11
Limitations

Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias.

Interpretation

Give a cautious overall interpretation considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence.

Generalisability

Discuss the generalisability (external validity) of the study results.

Other Information

Funding

Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based.

None

The STROBE checklist is distributed under the terms of the Creative Commons Attribution License CC-BY. This checklist can be completed online using https://www.goodreports.org/, a tool made by the EQUATOR Network in collaboration with Penelope.ai.
Association between medication adherence and disease outcomes in hepatitis B-related cirrhosis patients: a population-based case-control study

| Journal: | BMJ Open |
|----------|----------|
| Manuscript ID | bmjopen-2021-059856.R1 |
| Article Type: | Original research |
| Date Submitted by the Author: | 05-May-2022 |
| Complete List of Authors: | Fu, Kuo-Yu; China Medical University, Department of Health Services Administration  
Hsieh, Meng-Lun; Taichung Veterans General Hospital, Department of Internal Medicine  
Chen, Jou-An; China Medical University, Department of Health Services Administration  
Hsieh, Vivian Chia-Rong; China Medical University, Department of Health Services Administration |
| Primary Subject Heading: | Gastroenterology and hepatology |
| Secondary Subject Heading: | Epidemiology, Public health |
| Keywords: | EPIDEMIOLOGY, Hepatology < INTERNAL MEDICINE, PUBLIC HEALTH |
I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd (“BMJ”) its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge (“APC”) for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author’s Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.
Original Paper

**Association between medication adherence and disease outcomes in hepatitis B-related cirrhosis patients: a population-based case-control study**

Running title: Drug adherence in hepatitis B related cirrhosis

Kuo-Yu Fu, MHA#,1, Meng-Lun Hsieh, MD2, Jou-An Chen, MHA1, Vivian Chia-Rong Hsieh, PhD#,1,*

1 Department of Health Services Administration, China Medical University, Taichung 406, Taiwan;
2 Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 407, Taiwan;
# Contributed equally.

*Correspondence to:
Vivian Chia-Rong Hsieh, MSc, PhD.
Department of Health Services Administration,
China Medical University
No. 100, Sec. 1, Jingmao Rd.,
Beitun District, Taichung 406, Taiwan
Email: hsiechiarong@gmail.com

Word count: 2,836
Tables: 4
Figures: 0
Abstract

Objective
To evaluate medication adherence among hepatitis B-related cirrhosis patients who developed decompensation and mortality and to examine the association between medication adherence and patients’ disease outcomes.

Design
In this retrospective case-control study, patients aged over 20 years old and diagnosed with both chronic hepatitis B and cirrhosis from 2007 to 2016 are identified using a population-based medical claims database. Two prognosis end points (decompensation and mortality) are used respectively to classify subjects into two different case-control sets. Study groups are propensity-score matched. Medication possession ratio (MPR) is used as a measure of treatment adherence for oral antiviral drugs, and conditional logistic regression models are used to estimate the odds of decompensation and mortality after accounting for MPR and other covariates.

Results
Between decompensated and compensated patients, longer term treatment adherence is seen higher in the compensated group versus the decompensated group: 1-year MPR (0.65±0.43 vs. 0.57±0.53), and 6-month MPR (0.79±0.52 vs. 0.76±0.79). On the contrary, 3-month adherence is higher in the decompensated group (1.00±1.15 vs. 0.96±0.79). For patients with and without mortality, drug adherence is ubiquitously higher in the alive group regardless of follow-up length: 1-year MPR (0.62±0.44 vs. 0.50±0.51), 6-month MPR (0.78±0.62 vs. 0.69±0.72) and 3-month MPR (0.97±0.91 vs. 0.96±1.12). After accounting for confounding variables, we find that the likelihood of complicated cirrhosis is significantly lower in more adherent patients and the benefit increases with more persistent adherence (log 1-year MPR OR: 0.75, 95% CI: 0.73-0.77). Similar results are observed for the adjusted likelihood of
mortality (log 1-year MPR OR: 0.70, 95% CI: 0.68-0.72).

Conclusions

Long term patient adherence to antiviral therapy remains inadequate in HBV-related cirrhosis patients. Their adherence to oral antiviral therapy appears to be inversely associated with decompensation and mortality.

Keywords: cirrhosis; hepatitis B; medication adherence; prognosis; decompensation; mortality

Strengths and Limitations of this study:

- No study has yet provided empirical evidence on the adherence rate of HBV-related cirrhosis patients on oral antiviral therapy and quantified the level of adherence required to avert adverse outcomes.
- Medication possession ratio (MPR) can be a robust estimate of treatment adherence over time as it takes into account the period when patient stops and resumes medication.
- This is a population-based case-control study using nationwide medical claims data, and the distribution of general characteristics of our study subjects appears to be similar to the general demographics of HBV-related cirrhosis patients.
- We have no imaging data or laboratory test results to confirm the severity or the diagnosis of cirrhosis in each of our subjects.
- Adherent level estimated using MPR may not represent the actual medication adherence exhibited by the study subjects as it is calculated based on prescription history and not the actual uptake of medication by the patients.
Introduction

With the growing prevalence of chronic diseases globally, medication adherence to therapy has become one of the highly concerned issues in recent years. Patient adherence refers to the extent to which a patient complies with the doctor's orders or recommendations given by a healthcare provider. Unfortunately, patient adherence is generally not high. Statistics indicate that only about 50% of chronic disease patients worldwide taking medications in accordance with doctors' orders. This result not only leads to poor clinical treatment results, but also increases mortality and generates substantial economic burden.¹

Cirrhosis is an irreversible liver disease characterised by poor liver function due to long-term damage like alcohol use or viral infections such as chronic hepatitis B (CHB) and chronic hepatitis C (CHC). In southeast Asian nations, CHB- and CHC-related cirrhosis is particularly prevalent.² According to its natural clinical course and symptoms, cirrhosis can be divided into two stages of compensated (CC) and decompensated cirrhosis (DC). The former stage is characterised by an absence of complications, whereas the latter is an advanced condition with life-threatening conditions developed from elevated portal hypertension. DC is associated with complications such as varicose bleeding, ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, and hepatic encephalopathy.³ Previous findings suggest that the median survival time for patients with CC is 12 years and the treatment rate is about 70-80%, while the median survival time for patients with DC is less than two years and the treatment rate is about 50-60%.⁴ ⁵ Other related literature also showed that the death rate of patients with DC is 4 times that of healthy individuals, 30% of patients die within one month, and 63% of patients die within one year.⁶

For the treatment of cirrhosis, antiviral therapy has shown positive effect on the
improvement of cirrhosis and its complications. However, treatment adherence in chronic patients is usually not high, as they may have low perception of the effectiveness or necessity of prescribed medications. Under Taiwan’s single payer system, the National Health Insurance (NHI), hepatitis B virus (HBV) treatment is placed under a pay-for-performance scheme. Oral antiviral drugs that have been approved for the treatment of HBV infection are entecavir, tenofovir disoproxil fumarate, tenofovir alafenamide, lamivudine, telbivudine, and adefovir dipivoxil. Tenofovir alafenamide, however, was not reimbursed until 2017. These antiviral drugs can be prescribed primarily based on clinician’s evaluation of patient’s HBsAg, HBeAg, alanine aminotransferase (ALT), and HBV DNA status under the NHI Drug Dispensing Items and Fee Schedule guidelines. There is a scarcity of studies illustrating the benefits of maintaining adherence with viral hepatitis-related cirrhosis patients. Moreover, as many studies have discussed the advantages of good treatment adherence, no study has yet provided empirical evidence on the pragmatic adherence rate of cirrhosis patients on antiviral therapy and quantified the level of adherence required to avert adverse outcomes, e.g., how adherent are cirrhotic patients to their treatment regimens and how adherent is sufficient to prevent disease progression reduce complication risks among these patients.

The objective of the present study is to first compare the medication adherence between HBV-related cirrhosis patients with and without decompensation, and to subsequently analyse the association between medication adherence and the patients’ prognosis (decompensation and mortality). To ensure that both short- and long-term adherence is considered, medication possession ratio was calculated for three-month, six-month and one-year periods.
Materials and Methods

Study design and subject selection

This is a retrospective case-control study using secondary data from an administrative claims-based database released by the Health and Welfare Data Science Center, Ministry of Health and Welfare (HWDC, MOHW), Taiwan. Patients who were aged over 20 years old and diagnosed with chronic hepatitis B (ICD-9-CM: 070.32, 070.33, V02.61) and cirrhosis (571.4, 571.5, 571.8) between 2007 and 2016 were first identified from the database. To ensure that the cirrhosis of our study subjects is derived from hepatitis B, patients diagnosed with the following conditions were excluded: alcoholic fatty liver cirrhosis (571.0), alcoholic cirrhosis (571.1, 571.2, 571.3), biliary cirrhosis (571.6), congenital cirrhosis (777.8), hemochromatosis (275.0), or the syphilitic cirrhosis (095.3).

Two prognosis endpoints were used respectively to classify study subjects into two different case-control sets: 1) presence of complications (case: decompensated cirrhosis, control: compensated cirrhosis), 2) mortality (case: dead, control: alive). These endpoints must occur following the diagnoses of chronic hepatitis B and cirrhosis. Decompensation was defined when the subject had been diagnosed with at least one of the following conditions: esophageal variceal bleeding (456.0), ascites (789.5), spontaneous bacterial peritonitis (567.23), hepatorenal syndrome (572.4), and hepatic encephalopathy (572.2), while compensation was considered in the absence of any of the above complications. Mortality was ascertained if death was recorded after the date of diagnosis for cirrhosis. Each case-control set was matched 1:1 using propensity score matching according to gender, age, and post-onset medication interval. Post-onset medication interval was to ensure that the case and control patients were not too far apart in terms of their medical history (i.e., how long since they have been diagnosed with hepatitis B).
Medication and adherence measurements

Five oral antiviral drugs have been approved for the treatment of HBV infection in patients with relevant indications. In this study, HBV patients treated with nucleos(t)ide analogues (NUCs) were identified: lamivudine (LAM), adefovir dipivoxil (ADV), telbivudine (LdT), entecavir (ETV) and tenofovir disoproxil fumarate (TDF). Medication possession ratio (MPR) was calculated for 3, 6, and 12 months prior to the date of decompensation and mortality in subjects that were being prescribed with the antiviral medication(s). Thus, there should be no concern that MPR for cirrhotic patients included in this study would be lower due to complications. For controls, MPR was estimated for 3, 6, and 12 months prior to the end of the observation period. MPR is a commonly-used indirect measure of drug adherence and refers to the proportion of days a patient has a supply of drugs during the observation period. For the objective of this study, we solely consider medications associated with HBV-related cirrhosis, and not others. Under Taiwan’s national health insurance pay-for-performance payment scheme for chronic HBV therapy, antiviral medications should not overlap, as no multiple antiviral drugs should be prescribed concomitantly. Under this circumstance, patients would not be given more drugs prior to the date of next prescription. For this reason, we used MPR to estimate patient adherence, believing that the chance for multiple and overlapping drugs is unlikely (proportion-of-days-covered would be a better adherence measure if the chance of overlapping medication is high). Good adherence is when the MPR is greater than 0.75 or 0.80. Most studies use 0.80 as a cut-off point for determining good or poor adherence.

Statistical analyses
SAS version 9.4 statistical software package was used to perform statistical analyses in this study. Patient characteristics and treatment methods were descriptively analysed, and the results were presented in the form of means, standard deviations, frequencies, percentage, etc. For the distribution statistics and continuous data comparison between the groups, Wilcoxon’s rank-sum test was used. For categorical variables such as patient traits and treatment modalities, Chi-square test or Fisher's exact test was used to test the differences between study groups. Collinearity test was conducted to exclude any variables with collinearity problems. Natural logarithm (log) of MPR was also taken to standardise its distribution. Finally, for inferential statistics, conditional logistic regression models were used to estimate the odds of prognosis (decompensation or mortality) after accounting for MPR and other covariates. Odds ratio (OR) and 95% confidence interval for poor prognosis are presented as results in the included tables.

**Ethics approval**

This study was approved by China Medical University and Hospital ethics committee (CMUH107-REC2-105) and was supported by the following grants: MOST 107-2314-B-039-065-MY3 and CMU107-Z-04.

**Results**

From the population-based database, a total of 10,180 decompensated cirrhosis and 10,180 compensated cirrhosis patients are matched. Similarly, 9,724 patients who died from cirrhosis and 9,724 cirrhosis patients who were alive during the study period are identified and matched. In general, regardless of the prognosis (decompensation or death), medication adherence increases as time approaches closer
to the time of adverse outcome (Table 1). For example, 1-year, 6-month, and 3-month MPRs in decompensated and compensated cirrhotic subjects are 0.61±0.48, 0.77±0.67, and 0.98±0.99, respectively. A slightly lower MPR but similar pattern is found when we examine MPR in cirrhosis patients with and without mortality: 1-year, 6-month, and 3-month MPRs are 0.56±0.48, 0.74±0.67, and 0.97±1.02. It is worthy to note that long term (>3-month) MPRs are all shown to be under 0.80.

Table 2 shows the post-matching characteristics of study subject groups divided by prognosis. In the decompensated group, 34.8% (n=3,542) of patients experienced 2 or more complications, 33.6% (n=3,424) had ascites, while the compensated control group had no complications as expected. The pattern of NUC uptake differs significantly between the two groups: the top three most commonly used NUCs in decompensated patients are ETV (61.1%), LAM (14.2%), and TDF (10.4%), and ETV (59.6%), TDF (19.8%), LAM (9.58%) in compensated patients. The proportion of patients undergoing more than two NUC treatments is relatively higher in complicated cirrhosis patients (7.11% vs. 4.93%; p<0.001). Longer term treatment adherence seems higher on average in the compensated group versus decompensated group: 1-year MPR (0.65±0.43 vs. 0.57±0.53), and 6-month MPR (0.79±0.52 vs. 0.76±0.79). On the contrary, 3-month adherence is higher in the decompensated group (1.00±1.15 vs. 0.96±0.79).

In the set of analysis examining mortality as outcome, the occurrence of every complication is significantly higher in cirrhosis patients who died (cases) than in those who are still alive (controls) (Table 2). Most pronounced difference is seen in two or more concurrent complications (23.5% vs. 2.93%) and ascites (15.4% vs. 4.65%). Most of the control patients do not experience any complication (88.6%) unlike the case patients with just 45.5%. Drug adherence is ubiquitously higher in the alive group regardless of length of follow-up (p<0.001): 1-year MPR (0.62±0.44 vs.
0.50±0.51), 6-month MPR (0.78±0.62 vs. 0.69±0.72) and 3-month MPR (0.97±0.91 vs. 0.96±1.12).

After accounting for confounding variables, we find that the likelihood of complicated cirrhosis is significantly lower in more adherent patients. In the results from multivariate analysis presented in Table 3, longer persistent adherence (log 1-year MPR) is associated with most apparent decreased odds of decompensation (OR: 0.75, 95% CI: 0.73-0.77, p<0.001). Likelihood for the poor prognosis is slightly elevated when adherence continues for shorter span: log 6-month MPR (OR: 0.79, 95% CI: 0.76-0.81, p<0.001), and log 3-month MPR (OR: 0.85, 95% CI: 0.83-0.88, p<0.001). Older age is also found to be related to slightly increased odds of decompensation (p<0.001).

Similar results are observed for the adjusted likelihood of mortality: better adherence is also associated with lower chance of mortality particularly with longer adherence: log 1-year MPR (OR: 0.70, 95% CI: 0.68-0.72, p<0.001), log 6-month MPR (OR: 0.72, 95% CI: 0.69-0.75, p<0.001), and log 3-month MPR (OR: 0.78, 95% CI: 0.75-0.81, p<0.001) (Table 4). In addition, having two or more complications considerably increases the odds of mortality by 16-fold which is much higher than the other complication categories. Contrary to the increased risk of mortality imposed by older age, the use of NUCs generally averts patients from the adverse event.

Discussion

The present study provides useful information from a nationwide retrospective study of cirrhosis patients induced by viral hepatitis B. As we have observed, despite Taiwan’s readily accessible universal coverage health care system, patient adherence to antiviral therapy remains inadequate, particularly in the long run (i.e., 1-year MPR:...
0.56-0.61). This finding is consistent with previous studies from other countries examining adherent behaviour in CHB patients. More importantly, we demonstrate that the likelihood of poor prognosis is negatively associated with adherent behaviour, and the benefits of long-term adherence are evidently more pronounced than that of the short-term. The fact that patient adherence greatly escalates during the short time leading up to adverse outcomes indicates that patients’ healthcare seeking behaviours are still very reactive rather than proactive (i.e., proactive behaviour should indicate a consistent pattern of medication use since the point of diagnosis, and not particularly prior to the occurrence of complications). Furthermore, the occurrence of complications, such as HRS and HE, exacerbates the likelihood of mortality, especially if two or more are collectively observed.

Treatment adherence has been widely proven to be associated with better virology response and patient-reported outcomes in patients with CHB infection before progression to cirrhosis. Results of this study, however, show that adherence to antiviral therapy is inversely associated with the development of subsequent complications and death among HBV-related cirrhosis patients. After accounting for other confounding characteristics such as gender, age, type of complications, and treatment methods, this association still remains statistically significant. Therefore, we confirm that odds of subsequent poor prognosis are inversely linked to patients’ medication adherence. This is similar to a Taiwanese cohort study of 1315 treatment-naïve CHB-related cirrhosis patients; it is found that 4-year ETV therapy significantly decreases patients’ risk of cirrhotic complications and all-cause mortality. Another study conducted in Korean CHB patients reveal that poor adherence to ETV therapy is associated with increased risk of cirrhotic complications and all-cause mortality. As Taiwan offers universal coverage to healthcare and financial support to low-income households, affordability of
medication should not be a chief barrier to nonadherence, just as past studies have suggested.\textsuperscript{10,12} It is possible that, under our context of study, poor adherence may be due to patients’ low perception of treatment benefit or their reluctance to comply without experiencing obvious symptoms.\textsuperscript{10} Nevertheless, there also have been studies that report very good medication adherence to NUCs among patients with CHB. A US study using self-reported survey found an adherence rate of 100\% in 74.1\% of its subjects.\textsuperscript{19} Another study from the Netherlands reported 70\% of CHB patients presented an adherence rate of over 80\% towards entecavir.\textsuperscript{20} It is possible that the factors and the barriers associated with adherence to antiviral treatment among CHB patients are context- and/or culture-specific.\textsuperscript{21}

The distribution of general characteristics of our study subjects appears to be similar to the general demographics of HBV-related cirrhosis patients; here we find that these patients are mostly male with a mean age of approximately 60 years, which is similar to the demographics found in past studies.\textsuperscript{22,23} Among the used NUCs, patients have been predominantly prescribed entecavir, since it is still considered the first-line treatment for patients with CHB.\textsuperscript{24} The use of MPR as a measure of drug adherence has also been adopted in many previous studies.\textsuperscript{13,25,26} It is believed that MPR can be a robust estimate of treatment adherence over time as it takes into account the period when patient stops and resumes medication.\textsuperscript{25}

Nevertheless, our study is not without limitations. First, the primary source of data for this study is a medical claims-based database, hence, MPR is calculated based on prescription history and not the actual uptake of medication by the patients. Hence, the adherent level estimated using MPR may not represent the actual medication adherence exhibited by the study subjects. Second, although the population-based claims database provided us with an opportunity to study patient adherence on a large scale, we have no imaging data or laboratory test results to confirm the severity or the
diagnosis of cirrhosis in each of our subjects. Therefore, the variability in patients’ conditions and their consequent probability of disease progression cannot be considered. Since hepatocellular carcinoma (HCC) may also cause decompensation and mortality independent of cirrhosis, we cannot account for HCC developed before the study period without available data. Thus, it is possible that we may have underestimated the effect of medication adherence (i.e., even lower odds of decompensation and death for adherent behaviour after removing HCC-induced decompensation and mortality). Other important factors leading up to adverse prognosis may not be explored, including time since diagnosis and lifestyle factors. Nonetheless, with the high prevalence of HBV in the context under study, we have obtained a sufficient sample size for analyses and estimates for robust results.

In conclusion, findings of this study demonstrate that prompt follow-up and strict adherence to prescribed antiviral therapy should be highly endorsed in patients with HBV-related cirrhosis particularly by doctors, while a lack of adherence or non-adherence can be associated with pervasive threat to patients’ health, including transition to decompensation state and possible death. We hope that findings of this study would shed some light for future studies which may aim to investigate the rolling out of policies targeting the context-specific factors associated with poor adherence in cirrhosis patients, possibly including enhanced adherence counselling in clinical settings.

Summary of Study

The objective of the present study is to first compare the medication adherence between HBV-related cirrhosis patients with and without decompensation, and subsequently to analyse the association between medication adherence and the
patients’ prognosis (decompensation and mortality). Using medication-possession ratio as a measure for adherence, we find that patient adherence to therapy of cirrhosis remains inadequate compared with other countries. Patients lacking adherent behaviour, particularly in the long run, appear to have lower potential benefits of treatment intervention.

**Acknowledgments**

We would like to thank Dr. Cheng-Yuan Peng for his valuable input and contribution to this study.

**Contributors**

KY Fu, JA Chen, and VCR Hsieh were involved in design, data collection, data analysis, interpretation of results, and preparation of the initial manuscript.

ML Hsieh and VCR Hsieh were involved in critically appraising and revising the manuscript prior to approving the final version.

All authors approved the final version of the manuscript and the authorship list.

VCR Hsieh is guarantor of the article.

**Funding**

This project is supported in part by Taiwan’s Ministry of Science and Technology (MOST 107-2314-B-039-065-MY3) and China Medical University (CMU107-Z-04).

**Competing interests**

None declared.

**Patient and Public Involvement**
Patients or the public WERE NOT involved in the design, or conduct, or reporting, or dissemination plans of our research.

Data availability statement

No additional data available.
References

1. Celio J, Ninane F, Bugnon O, Schneider MP. Pharmacist-nurse collaborations in medication adherence-enhancing interventions: A review. *Patient Educ Couns* 2018;101:1175-1192.

2. GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet Gastroenterol Hepatol* 2020;5:245-266.

3. European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. *J Hepatol* 2018;69:406-460.

4. D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. *J Hepatol* 2006;44:217-231.

5. Shah AS, Amarapurkar DN. Natural history of cirrhosis of liver after first decompensation: a prospective study in India. *J Clin Exp Hepatol* 2018;8:50-57.

6. Arvaniti V, D’Amico G, Fede G, Manousou P, Tschatzis E, Pleguezuelo M, Burroughs AK. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. *Gastroenterology* 2010;139:1246-1256, 1256.e1-5.

7. Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. *J Hepatol* 2012;57:442-450.

8. Piotrowski D, Boroń-Kaczmarska A. Bacterial infections and hepatic encephalopathy in liver cirrhosis-prophylaxis and treatment. *Adv Med Sci* 2017;62:345-356.

9. Horne R, Chapman SCE, Parham R, Freemantle N, Forbes A, Cooper V. Understanding patients’ adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the Necessity-Concerns Framework. *PLoS One* 2013;8:e80633.

10. Hayward KL, Valery PC, Martin JH, et al. Medication beliefs predict medication adherence in ambulatory patients with decompensated cirrhosis. *World J Gastroenterol* 2017;23:7321-7331.

11. Allard N, Dev A, Dwyer J, Srivatsa G, Thompson A, Cowie B. Factors associated with poor adherence to antiviral treatment for hepatitis B. *J Viral Hepat* 2017;24:53-58.

12. Xu K, Liu LM, Farazi PA, et al. Adherence and perceived barriers to oral antiviral therapy for chronic hepatitis B. *Glob Health Action* 2018;11:1433987.

13. Allard NL, MacLachlan JH, Dev A, et al. Adherence in chronic hepatitis B:
associations between medication possession ratio and adverse viral outcomes. *BMC Gastroenterol* 2020;20:140.

14. Grossi G, Viganò M, Loglio A, Lampertico P. Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs). *Liver Int* 2017;37 Suppl 1:45-51.

15. Lieveld FI, van Vlerken LG, Siersema PD, van Erpecum KJ. Patient adherence to antiviral treatment for chronic hepatitis B and C: a systematic review. *Ann Hepatol* 2013;12:380-391.

16. Younossi ZM, Stepanova M, Younossi I, et al. Long-term effects of treatment for chronic HBV infection on patient-reported outcomes. *Clin Gastroenterol Hepatol* 2019;17:1641-1642.e1.

17. Su TH, Hu TH, Chen CY et al. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. *Liver Int* 2016;36:1755-1764.

18. Shin JW, Jung SW, Lee SB, et al. Medication nonadherence increases hepatocellular carcinoma, cirrhotic complications, and mortality in chronic hepatitis B patients treated with entecavir. *Am J Gastroenterol* 2018;113:998-1008.

19. Chotiyaputta W, Hongthanakorn C, Oberhelman K, Fontana RJ, Licari T, Lok ASF. Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical practice and correlation with virological breakthroughs. *J Viral Hepat* 2012;19:205-212.

20. van Vlerken L, Arends P, Lieveld FI, et al. Real life adherence of chronic hepatitis B patients to entecavir treatment. *Dig Liver Dis* 2015;47:577-583.

21. Kidd KE, Altman DG. Adherence in social context. *Control Clin Trials* 2000;21:184S-187S.

22. Hung TH, Tsai CC, Lee HF. Population-based study of Entecavir and long-term mortality in chronic hepatitis B–related decompensated liver cirrhosis. *Clin Res Hepatol Gastroenterol* 2019;43:694-699.

23. Rubin JB, Sundaram V, Lai JC. Gender differences among patients hospitalized with cirrhosis in the United States. *J Clin Gastroenterol* 2020;54:83-89.

24. Chien R, Kao JH, Peng CY, et al. Taiwan consensus statement on the management of chronic hepatitis B. *J Formos Med Assoc* 2019;118:7-38.

25. Friedman DS, Quigley HA, Gelb L, et al. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS). *Invest Ophthalmol Vis Sci* 2007;48:5052-5057.

26. Zhang Y, Kaplan CM, Baik SH, Chang CH, Lave JR. Medication adherence and
readmission after myocardial infarction in the Medicare population. *Am J Manag Care* 2014;20:e498-505.
Table 1. Descriptive statistics of medication adherence and prognosis among chronic hepatitis B virus-related cirrhosis patients.

| Dependent variable | Medication Adherence (MPR) | Mean | Standard deviation | Median |
|--------------------|-----------------------------|------|--------------------|--------|
| Decompensation     | 3-month                     | 0.98 | 0.99               | 0.93   |
|                    | 6-month                     | 0.77 | 0.67               | 0.74   |
|                    | 1-year                      | 0.61 | 0.48               | 0.54   |
| Death              | 3-month                     | 0.97 | 1.02               | 0.92   |
|                    | 6-month                     | 0.74 | 0.67               | 0.67   |
|                    | 1-year                      | 0.56 | 0.48               | 0.46   |
**Table 2. Post-matching characteristic profile of cirrhosis subjects by prognosis (decompensation/compensation; and death/alive).**

| Variable                          | Decompensated | Compensated | P-value | Death       | Alive       | P-value |
|-----------------------------------|---------------|-------------|---------|-------------|-------------|---------|
|                                   | n             | %           | n       | %           |             | n       | %       |         |             |             |          |
| **Total**                         | 10,180        | 50.0        | 10,180  | 50.0        |             | 9,724   | 50.0   | 1.00    | 9,724       | 50.0       | 1.00    |
| **Sex**                           |               |             |         |             |             |         |        |         |             |             |          |
| Male                              | 7,453         | 73.2        | 7,453   | 73.2        |             | 7,780   | 80.0   | 1.00    | 7,780       | 80.0       | 1.00    |
| Female                            | 2,727         | 26.8        | 2,727   | 26.8        |             | 1,944   | 20.0   |         | 1,944       | 20.0       |         |
| **Age (mean, SD)**                |               |             |         |             |             |         |        | 0.06    |             |             |          |
| Male                              | 60.1          | 12.0        | 59.7    | 12.0        | 0.06        | 60.4    | 12.0   | 0.06    | 60.0         | 12.0       | 0.06    |
| Varicose vein bleeding            |               |             |         |             | <0.001      | 156     | 1.60   | 0.47    |             |             | <0.001  |
| Ascites                           | 3,424         | 33.6        | 0       | 0           |             | 1,498   | 15.4   | 452     | 4.65         |             |         |
| SBP                               | 414           | 4.07        | 0       | 0           |             | 187     | 1.92   | 57      | 0.59         |             |         |
| HRS                               | 153           | 1.50        | 0       | 0           |             | 101     | 1.04   | 18      | 0.19         |             |         |
| HE                                | 2,121         | 20.8        | 0       | 0           |             | 1,078   | 11.1   | 247     | 2.54         |             |         |
| Two or more complications         | 3,542         | 34.8        | 0       | 0           |             | 2,281   | 23.5   | 285     | 2.93         |             |         |
| None                              | 0             | 0           | 10,180  | 100.0       | <0.001      | 4,423   | 45.5   | 8,619   | 88.6         | <0.001      |         |
| **NUs**                           |               |             |         |             |             |         |        |         |             |             |          |
| LAM                               | 1,448         | 14.2        | 975     | 9.58        |             | 1,352   | 13.9   | 1,117   | 11.5         |             |         |
| ADV                               | 74            | 0.73        | 85      | 0.83        |             | 77      | 0.79   | 83      | 0.85         |             |         |
| LdT                               | 656           | 6.44        | 533     | 5.24        |             | 759     | 7.81   | 533     | 5.48         |             |         |
| ETV                               | 6,216         | 61.1        | 6,065   | 59.6        |             | 5,912   | 60.8   | 5,693   | 58.6         |             |         |
| TDF                               | 1,062         | 10.4        | 2,020   | 19.8        |             | 917     | 9.43   | 1,881   | 19.3         |             |         |
| Two or more combined treatments   | 724           | 7.11        | 502     | 4.93        | <0.001      | 707     | 7.27   | 417     | 4.29         | <0.001      |         |
| **MPR (mean, SD)**                |               |             |         |             |             |         |        |         |             |             |          |
| 3-month                           | 1.00          | 1.15        | 0.96    | 0.79        | <0.001      | 0.96    | 1.12   | 0.97    | 0.91         | <0.001      |         |
| 6-month                           | 0.76          | 0.79        | 0.79    | 0.52        | <0.001      | 0.69    | 0.72   | 0.78    | 0.62         | <0.001      |         |
| 1-year                            | 0.57          | 0.53        | 0.65    | 0.43        | <0.001      | 0.50    | 0.51   | 0.62    | 0.44         | <0.001      |         |

Abbreviations: SBP, spontaneous bacterial peritonitis; HRS, hepatorenal syndrome; HE, hepatic encephalopathy. NUCs, nucleos(t)ide analogues; LAM, lamivudine only; ADV, adefovir dipivoxil only; LdT, telbivudine only; ETV, entecavir only; TDF, tenofovir disoproxil fumarate only; MPR, medication possession ratio.
| Variable | Crude | Adjusted log 3-month MPR | Adjusted log 6-month MPR | Adjusted log 1-year MPR |
|----------|-------|--------------------------|--------------------------|-------------------------|
|          | OR    | 95% CI                   | P-value                  | OR                      | 95% CI                   | P-value                  | OR                      | 95% CI                   | P-value                  |
| Medication adherence |       |                          |                          |                          |                          |                          |                          |                          |                          |
| log 3-month MPR | 0.85  | 0.82 0.88                | <0.001                   | 0.85                    | 0.83 0.88                | <0.001                   | 0.79                    | 0.76 0.81                | <0.001                   |
| log 6-month MPR  | 0.78  | 0.76 0.81                | <0.001                   |                          |                          |                          | 0.75                    | 0.73 0.77                | <0.001                   |
| log 1-yr MPR     | 0.75  | 0.73 0.77                | <0.001                   |                          |                          |                          |                        |                          |                          |
| Age            | 1.04  | 1.03 1.04                | <0.001                   | 1.04                    | 1.03 1.04                | <0.001                   | 1.03                    | 1.03 1.04                | <0.001                   |
| NUCs           |       |                          |                          |                          |                          |                          |                          |                          |                          |
| LAM            | 1.08  | 0.94 1.25                | 0.27                     | 1.09                    | 0.95 1.27                | 0.22                     | 1.12                    | 0.97 1.29                | 0.14                     |
| ADV            | 0.63  | 0.45 0.88                | 0.007                    | 0.63                    | 0.45 0.88                | 0.007                    | 0.64                    | 0.45 0.90                | 0.01                     |
| LdT            | 0.88  | 0.75 1.04                | 0.14                     | 0.89                    | 0.76 1.05                | 0.18                     | 0.92                    | 0.78 1.08                | 0.30                     |
| ETV            | 0.73  | 0.65 0.83                | <0.001                   | 0.73                    | 0.65 0.83                | <0.001                   | 0.75                    | 0.67 0.85                | <0.001                   |
| TDF            | 0.38  | 0.33 0.43                | <0.001                   | 0.38                    | 0.33 0.44                | <0.001                   | 0.39                    | 0.34 0.45                | <0.001                   |
| Two or more    | 1     |                          |                          | 1                       |                          |                          | 1                       |                          |                          |

NUCs, nucleos(t)ide analogues; LAM, lamivudine only; ADV, adefovir dipivoxil only; LdT, telbivudine only; ETV, entecavir only; TDF, tenofovir disoproxil fumarate only; MPR, medication possession ratio.
Table 4. Conditional Logistic regression analysis of mortality in cirrhosis patients.

| Variable                   | Crude OR (95% CI) | P-value | Adjusted log 3-month MPR OR (95% CI) | P-value | Adjusted log 6-month MPR OR (95% CI) | P-value | Adjusted log 1-year MPR OR (95% CI) | P-value |
|---------------------------|-------------------|---------|-------------------------------------|---------|-------------------------------------|---------|------------------------------------|---------|
| Medication adherence      |                   |         |                                     |         |                                     |         |                                    |         |
| log 3-month MPR           | 0.80 (0.78, 0.83) | <0.001  | 0.78 (0.75, 0.81)                  | <0.001  |                                     |         |                                    |         |
| log 6-month MPR           | 0.72 (0.70, 0.74) | <0.001  |                                     |         | 0.72 (0.69, 0.75)                  | <0.001  |                                    |         |
| log 1-yr MPR              | 0.69 (0.67, 0.71) | <0.001  | 1.03 (1.02, 1.04)                  | <0.001  | 1.03 (1.02, 1.04)                  | <0.001  | 1.03 (1.02, 1.04)                  | <0.001  |
| Age                       | 1.04 (1.03, 1.05) | <0.001  | 1.03 (1.02, 1.04)                  | <0.001  | 1.03 (1.02, 1.04)                  | <0.001  | 1.03 (1.02, 1.04)                  | <0.001  |
| Complications             |                   |         |                                     |         |                                     |         |                                    |         |
| Varicose vein bleeding    | 6.00 (4.20, 8.83) | <0.001  | 6.57 (4.53, 9.52)                  | <0.001  | 6.71 (4.62, 9.76)                  | <0.001  | 6.65 (4.57, 9.68)                  | <0.001  |
| Ascites                   | 6.73 (5.90, 7.67) | <0.001  | 6.58 (5.76, 7.50)                  | <0.001  | 6.55 (5.74, 7.48)                  | <0.001  | 6.47 (5.66, 7.40)                  | <0.001  |
| SBP                       | 7.41 (5.28, 10.4) | <0.001  | 7.22 (5.12, 10.2)                  | <0.001  | 6.93 (4.89, 9.81)                  | <0.001  | 6.71 (4.73, 9.54)                  | <0.001  |
| HRS                       | 12.5 (7.17, 21.9) | <0.001  | 12.7 (7.18, 22.5)                  | <0.001  | 12.0 (6.71, 21.4)                  | <0.001  | 11.3 (6.30, 20.4)                  | <0.001  |
| HE                        | 9.18 (7.76, 10.9) | <0.001  | 8.98 (7.58, 10.6)                  | <0.001  | 8.71 (7.34, 10.3)                  | <0.001  | 8.45 (7.11, 10.0)                  | <0.001  |
| Two or more               | 15.7 (13.5, 18.2) | <0.001  | 16.1 (13.8, 18.7)                  | <0.001  | 16.2 (13.9, 18.8)                  | <0.001  | 16.0 (13.7, 18.6)                  | <0.001  |
| None                      | 1                  |         |                                     | 1       |                                     |         |                                    |         |
| NUCs                      |                   |         |                                     |         |                                     |         |                                    |         |
| LAM                       | 0.71 (0.61, 0.82) | <0.001  | 0.71 (0.59, 0.85)                  | <0.001  | 0.71 (0.59, 0.86)                  | <0.001  | 0.74 (0.61, 0.89)                  | <0.001  |
| ADV                       | 0.55 (0.39, 0.77) | <0.001  | 0.65 (0.43, 0.97)                  | 0.04    | 0.68 (0.45, 1.03)                  | 0.07    | 0.75 (0.49, 1.15)                  | 0.18    |
| LdT                       | 0.84 (0.71, 1.00) | 0.04    | 1.00 (0.82, 1.23)                  | 0.99    | 1.03 (0.84, 1.27)                  | 0.75    | 1.08 (0.88, 1.33)                  | 0.46    |
| TDF                       | 0.62 (0.54, 0.70) | <0.001  | 0.72 (0.62, 0.84)                  | <0.001  | 0.74 (0.63, 0.86)                  | <0.001  | 0.77 (0.66, 0.91)                  | <0.001  |
| Two or more               | 0.29 (0.25, 0.34) | <0.001  | 0.41 (0.34, 0.49)                  | <0.001  | 0.43 (0.36, 0.51)                  | <0.001  | 0.45 (0.37, 0.54)                  | <0.001  |
| combined treatments       | 1                  |         |                                     | 1       |                                     |         |                                    |         |
SBP, spontaneous bacterial peritonitis; HRS, hepatorenal syndrome; HE, hepatic encephalopathy. NUCs, nucleos(t)ide analogues; LAM, lamivudine only; ADV, adefovir dipivoxil only; LdT, telbivudine only; ETV, entecavir only; TDF, tenofovir disoproxil fumarate only; MPR, medication possession ratio.
Reporting checklist for case-control study.

Based on the STROBE case-control guidelines.

**Instructions to authors**

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the STROBE case-control reporting guidelines, and cite them as:

von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

| Reporting Item | Page Number |
|----------------|-------------|
| Title and abstract | |
| Title | #1a | Indicate the study’s design with a commonly used term in the title or the abstract | p.1 |
| Abstract | #1b | Provide in the abstract an informative and balanced summary | p.2 |
of what was done and what was found

Introduction

Background / rationale  #2 Explain the scientific background and rationale for the investigation being reported  p.4

Objectives  #3 State specific objectives, including any prespecified hypotheses  p.5

Methods

Study design  #4 Present key elements of study design early in the paper  p.5-6

Setting  #5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection  p.5-6

Eligibility criteria  #6a Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls. For matched studies, give matching criteria and the number of controls per case  p.5-6

Eligibility criteria  #6b For matched studies, give matching criteria and the number of controls per case  p.6

#7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable  p.6-7

Data sources / measurement  #8 For each variable of interest give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one
Bias  #9 Describe any efforts to address potential sources of bias  NA

Study size  #10 Explain how the study size was arrived at  p.5-6

Quantitative  #11 Explain how quantitative variables were handled in the  p.12
variables analyses. If applicable, describe which groupings were
chosen, and why

Statistical  #12a Describe all statistical methods, including those used to control  p.7
methods for confounding

Statistical  #12b Describe any methods used to examine subgroups and  NA
methods interactions

Statistical  #12c Explain how missing data were addressed  NA
methods

Statistical  #12d If applicable, explain how matching of cases and controls was  p.6
methods addressed

Statistical  #12e Describe any sensitivity analyses  NA
methods

Results

Participants  #13a Report numbers of individuals at each stage of study—eg  p.8
numbers potentially eligible, examined for eligibility, confirmed
eligible, included in the study, completing follow-up, and
analysed. Give information separately for cases and controls.

Participants  #13b Give reasons for non-participation at each stage  NA
Participants  #13c Consider use of a flow diagram  NA

Descriptive data  #14a Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders. Give information separately for cases and controls  p.8

Descriptive data  #14b Indicate number of participants with missing data for each variable of interest  NA

Outcome data  #15 Report numbers in each exposure category, or summary measures of exposure. Give information separately for cases and controls  p.8

Main results  #16a Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included  p.8-9

Main results  #16b Report category boundaries when continuous variables were categorized  p.8-9

Main results  #16c If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period  NA

Other analyses  #17 Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses  NA

Discussion

Key results  #18 Summarise key results with reference to study objectives  p.10-11
Limitations #19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias.

Interpretation #20 Give a cautious overall interpretation considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence.

Generalisability #21 Discuss the generalisability (external validity) of the study results.

Other Information

Funding #22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based.

None The STROBE checklist is distributed under the terms of the Creative Commons Attribution License CC-BY. This checklist can be completed online using https://www.goodreports.org/, a tool made by the EQUATOR Network in collaboration with Penelope.ai.